Eli Lilly and Co. on Friday, Nov. 21 became the first health care company to surpass a $1 trillion market valuation, driven by intense investor demand for its fast-growing weight-loss drug portfolio.
Read MoreShares of Eli Lilly and Novo Nordisk fell Friday, Oct. 17 after Pres. Donald Trump said the price of the weight-loss drug Ozempic could soon drop to $150 a month.
Read MoreLawsuits from at least 26 patients have been filed in Marion County against Eli Lilly and Co. for its marketing of the drugs GLP-1 Trulicity and Mounjaro, claiming the treatments for diabetes and obesity had adverse side effects that the company downplayed or did not mention in advertising.
Read MoreTo fight cheaper alternative versions of its weight loss drug, Eli Lilly & Co. have lowered prices of Zepbound vials.
Read MoreAdipo Therapeutics, LLC, a late pre-clinical biopharmaceutical company developing treatments for obesity and related metabolic disorders, announced the positive results for a key study demonstrating promising results using human tissue samples.
Read MoreShares of Eli Lilly and Co. took a two-day slide after competitor Roche announced positive results in an early-stage study on its obesity drug.
Read More
